![]() |
Questionnaire |
| Home |
|
The John Radcliffe Hospital Haematology Department, Oxford, has agreed to head a small patient trial to test Dr Carmen Wheatley's hypothesis (see Hypothesis), which will test vitamin B12 in the treatment of MGUS, the pre-cancer stage, from which 1 out of 4 patients can be expected to progress to Multiple Myeloma, or other related conditions, such as Waldenstrom's, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndrome, Macroglobulinaemia, Myelofibrosis, Polycythaemia/Vera/Rubra, Essential Thrombocythaemia, and certain lymphomas, such as Lymphocytic Lymphoma. Orthomolecular Oncology (Survive Cancer) and the John Radcliffe are currently finalising the protocol for the MGUS trial and costing it. The charity is in the process of fundraising for the trial, and as soon as the money is in place we hope to go ahead. We will post the final protocol, and a list of all the hospitals participating in the study as soon as these are available, so that anyone wishing to take part will be able to contact the hospital nearest to them. Depending on the results of this patient trial to test vitamin B12 in the treatment of MGUS, the charity plans to do a follow-up trial to test vitamin B12 in the treatment of Multiple Myeloma. As MGUS/Multiple Myeloma is still a relatively rare condition (although the incidence is increasing), and Myeloma is still one of the most difficult blood cancers in terms of finding a cure, pooling any information is of great value. If you currently have MGUS/Myeloma, and would be interested in taking part in the proposed patient trials, you might like to fill in the following questionnaire, which is for information-gathering about this condition. In the event that the trial gets the go-ahead, and you are considered suitable to take part, the information on your questionnaire will form part of the study. Orthomolecular Oncology (Survive Cancer) undertakes to treat your personal details with total confidentiality, and we would not pass them on to any of the centres running the MGUS/Myeloma patient trials without your express permission. Thank you for your help. If you do not feel well enough to do this, perhaps a close friend or relative could do it for you.
There are two options for filling out the questionnaire.
If you choose to use the on-line form, please remember that e-mail is not very secure. Due to the number of questions we advise that, once the page has fully opened in your browser, you disconnect from the Internet whilst composing your answers. The compiled replies will be present as an e-mail in your "Out" folder in your e-mail programme, and will be sent the next time you log on. If you remain on-line it will be sent immediately. Not all browsers treat this method of submission in the same manner, so please check your outgoing email before sending, to ensure your details have been correctly compiled. Postal address: |